Coherus Oncology (CHRS) Operating Income (2013 - 2026)
Coherus Oncology (CHRS) reported Operating Income of -$36.2 million for Q1 2026, up 20.43% on a YoY basis from -$30.0 million in Q1 2025, and up 21.21% sequentially from -$45.9 million in Q4 2025.
Coherus Oncology (CHRS) Operating Income (2013 - 2026) Analysis & Trends
Coherus Oncology (CHRS) has 14 years of Operating Income data on file, last reported at -$36.2 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income rose 20.43% year-over-year to -$36.2 million; the trailing twelve-month figure through Mar 2026 stood at -$171.8 million (up 3.07% YoY), and the FY2025 full-year result was -$181.1 million, up 9.28% from the prior year.
- Operating Income advanced to -$36.2 million in Q1 2026, from -$45.9 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$32.0 million in Q3 2023 to a low of -$80.9 million in Q1 2022.
- A 5-year average of -$51.6 million and a median of -$45.5 million in 2025 frame the typical range for Operating Income.
- Across the five-year window, Operating Income slumped 145.37% in 2022 and soared 60.22% in 2023, its largest moves.
- Tracing CHRS's Operating Income over 5 years: stood at -$51.5 million in 2022, then slumped by 33.81% to -$68.9 million in 2023, then soared by 34.14% to -$45.4 million in 2024, then slipped by 1.09% to -$45.9 million in 2025, then gained by 21.21% to -$36.2 million in 2026.
- Business Quant data shows CHRS's Operating Income at -$36.2 million in Q1 2026, -$45.9 million in Q4 2025, and -$44.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Coherus Oncology | 194.37 Mn | 27.32 Mn | 8.50 Mn | -36.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.15 Mn |
| Dec 31, 2025 | -45.88 Mn |
| Sep 30, 2025 | -44.33 Mn |
| Jun 30, 2025 | -45.49 Mn |
| Mar 31, 2025 | -45.44 Mn |
| Dec 31, 2024 | -45.38 Mn |
| Sep 30, 2024 | -46.86 Mn |
| Jun 30, 2024 | -39.63 Mn |
| Mar 31, 2024 | -67.79 Mn |
| Dec 31, 2023 | -68.91 Mn |
| Sep 30, 2023 | -32.01 Mn |
| Jun 30, 2023 | -34.54 Mn |
| Mar 31, 2023 | -67.75 Mn |
| Dec 31, 2022 | -51.49 Mn |
| Sep 30, 2022 | -80.45 Mn |
| Jun 30, 2022 | -44.01 Mn |
| Mar 31, 2022 | -80.93 Mn |
| Dec 31, 2021 | -39.55 Mn |
| Sep 30, 2021 | -32.79 Mn |
| Jun 30, 2021 | -24.16 Mn |